Top Abstract Purchase Related
Home
>
Node
>
Subnode

Thyroid dysfunction in patients treated with tyrosine kinase inhibitors

Przytulska, J.; Tupikowski, K.; Bednarek-Tupikowska, G.

Polski Merkuriusz Lekarski Organ Polskiego Towarzystwa Lekarskiego 36(211): 42-44

2014

ISSN/ISBN: 1426-9686
PMID: 24645578
Document Number: 673752
Tyrosine kinase Inhibitors are relatively new drugs used for treatment of several malignancies. The treatment is generally well tolerated, incidence of side effects of significant intensity is low. Hypothyroidism is a frequent complication, the mechanism and guidelines on endocrine treatment remain controversial. Observations indicate that hypothyroidism during treatment is correlated with higher probability of better response to treatment. Further research is necessary to establish guidelines on thyroid function tests and indications for treatment of hypothyroidism.

Document emailed within 1 workday
Secure & encrypted payments

Levy, B.P.; Rao, P.; Becker, D.J.; Becker, K. 2016: Attacking a Moving Target: Understanding Resistance and Managing Progression in EGFR-Positive Lung Cancer Patients Treated with Tyrosine Kinase Inhibitors Oncology 30(7): 601-612
Mahon, F.-X. 2019: When can tyrosine kinase inhibitors be discontinued in patients with chronic myeloid leukemia? Clinical Advances in Hematology and Oncology: H&o 17(2): 101-103
Dou, X.L.; Wang, S.S.; Fang, J.L.; Yu, L.; Ren, X.; Huang, X.J.; Jiang, Q. 2018: Hepatic adverse events associated with tyrosine kinase inhibitors in patients with chronic myeloid leukemia Zhonghua Nei Ke Za Zhi 57(9): 649-655
Bagadi, S.; Saikia, T.; Pany, A.; Das, B. 2011: Analysis of ABL Kinase Domain Mutations Conferring Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Cases from India Clinical Laboratory 57(7-8): 619-623
Goldman, J. 2004: CML resistance to tyrosine kinase inhibitors: how is the laboratory to tell? Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology 10(3): 181-184
Pang, S.H.; Guo, Z.R.; Liang, X.T. 1997: Synthesis and biological activity of tyrosine protein kinase inhibitors Yao Xue Xue Bao 32(7): 515-523
Turkina, A.G.; Domracheva, E.V.; Vorontsova, A.V.; Aseeva, E.A.; Vinogradova, O.I.; Stakhina, O.V.; Gusarova, G.A.; Diagileva, O.A.; Semenova, E.A.; Vakhrusheva, M.V.; Kolosheĭnova, T.I.; Abakumov, E.M.; Chelysheva, E.I.; Goriacheva, S.R.; Ivanova, T.V.; Zakharova, E.S.; Kolosova, L.I.; Zakharova, A.V.; Naumova, I.N.; Diachenko, L.V.; Kulikov, S.M.; Kovaleva, L.G.; Khoroshko, N.D. 2009: Trisomy of chromosome 8 in Ph-negative cells of the bone marrow in patients with chronic myeloid leukemia treated with inhibitors of BCR-ABL tyrosine kinases Terapevticheskii Arkhiv 81(7): 29-36
Shepherd, F.A. 2016: Should EGFR tyrosine kinase inhibitors be used in non-small cell lung cancer in the absence of EGFR mutations? Yes, there is a role for EGFR TKIs in these patients Clinical Advances in Hematology and Oncology: H&o 14(1): 41-43
Reid, T-Elinor.; Fortunak, J.M.; Wutoh, A.; Simon Wang, X. 2016: Cheminfomatic-based Drug Discovery of Human Tyrosine Kinase Inhibitors Current Topics in Medicinal Chemistry 16(13): 1452-1462
Jiang, J.-f.; Chen, X.-y.; Zhong, D.-f. 2016: Metabolic research of domestically developed small molecule tyrosine kinase inhibitors Yao Xue Xue Bao 51(2): 248-256
Sheng, J.Z.; Wong, N.S.; Wang, H.X.; Wong, T.M. 1997: Pertussis toxin, but not tyrosine kinase inhibitors, abolishes effects of U-50488H on [Ca2+]i in myocytes American Journal of Physiology 272(2 Pt 1): C560-C564
Xu, C.-a.; Su, H.; Liu, J.-l.; Li, L.; Zou, H.-w. 2011: Value of serum carcinoembryonic antigen in prediction of chemotherapy efficacy and prognosis in patients with advanced non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitor Zhonghua Zhong Liu Za Zhi 33(6): 436-441
Bhatia, R.; Munthe, H.A.; Verfaillie, C.M. 1998: Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors Leukemia 12(11): 1708-1717
Aytekin, A.; Ciltas, A.; Sahinli, H.; Benekli, M. 2016: The role of tyrosine kinase inhibitors in the treatment of renal cell carcinoma with brain metastases Journal of BUON: Official Journal of the Balkan Union of Oncology 21(1): 281-282
Ghosh, S.; Narla, R.K.; Zheng, Y.; Liu, X.P.; Jun, X.; Mao, C.; Sudbeck, E.A.; Uckun, F.M. 1999: Structure-based design of potent inhibitors of EGF-receptor tyrosine kinase as anti-cancer agents Anti-Cancer Drug Design 14(5): 403-410
2016: (S013) Spine Stereotactic Radiosurgery With Concurrent Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma Oncology 30 Suppl
Xu, J.; Cao, H. 2013: Molecular mechanism and therapeutic strategy for resistance to tyrosine kinase inhibitors in targeted treatment of gastrointestinal stromal tumors Zhonghua Wei Chang Wai Ke Za Zhi 16(3): 288-291
Kharbanda, S.; Yuan, Z.M.; Taneja, N.; Weichselbaum, R.; Kufe, D. 1994: p56/p53lyn tyrosine kinase activation in mammalian cells treated with mitomycin C Oncogene 9(10): 3005-3011
Hargreaves, P.G.; Licking, E.F.; Sargeant, P.; Sage, S.O.; Barnes, M.J.; Farndale, R.W. 1994: The tyrosine kinase inhibitors, genistein and methyl 2,5-dihydroxycinnamate, inhibit the release of (3H)arachidonate from human platelets stimulated by thrombin or collagen Thrombosis and Haemostasis 72(4): 634-642
Morse, M.A. 2001: American Society of Clinical Oncology - 37th Annual Meeting. Small molecule tyrosine kinase inhibitors. 12-15 May 2001, San Francisco, CA, USA IDrugs: the investigational drugs journal 4(8): 857-859